Study S002615

Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07014709
Acronym: IPMN-GLP1RA
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 30
Start: 2025-05-31
Primary completion: 2026-10-31
Lead sponsor: Hôpital Fribourgeois
Conditions: IPMN; IPMN, Pancreatic; GLP-1; Intraductal Papillary Mucinous Neoplasm of Pancreas; Glucagon-Like Peptide-1 Receptor Agonists
Interventions: DRUG:GLP1 receptor agonist
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensus [during the GLP1 RA treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003893	Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study. Lagger M, PloS one	2026	Protocol	PMID 42715243 DOI	cites ClinicalTrials.gov:NCT07014709; registry reference DERIVED:42715243